Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Act as a feedback negative regulator of signaling by receptor tyrosine kinases, through a mechanism that involves enhancement of receptor ubiquitination and accelerated intracellular degradation (By similarity).. Additionally we are shipping Lrig1 Proteins (10) and Lrig1 Kits (2) and many more products for this protein.
Showing 10 out of 68 products:
Mouse (Murine) Polyclonal Lrig1 Primary Antibody for FACS, ICC - ABIN4900308
Jensen, Driskell, Watt: Assaying proliferation and differentiation capacity of stem cells using disaggregated adult mouse epidermis. in Nature protocols 2010
Show all 9 references for 4900308
Mouse (Murine) Polyclonal Lrig1 Primary Antibody for WB - ABIN1881506
Ye, Gao, Xu, Zeng, Ou, Mao, Wang, He, Wang, Yang, Guo, Lei: Upregulation of LRIG1 suppresses malignant glioma cell growth by attenuating EGFR activity. in Journal of neuro-oncology 2009
Show all 2 references for 1881506
Mouse (Murine) Polyclonal Lrig1 Primary Antibody for FACS - ABIN4897517
Wong, Stange, Page, Buczacki, Wabik, Itami, van de Wetering, Poulsom, Wright, Trotter, Watt, Winton, Clevers, Jensen: Lrig1 controls intestinal stem-cell homeostasis by negative regulation of ErbB signalling. in Nature cell biology 2012
Human Polyclonal Lrig1 Primary Antibody for FACS, IHC - ABIN4900286
Oh, Lee, Choi, Suh, Shim, Song, Kim, Lee, Oh, Jeong, Cheong, Song, Kim: USP8 modulates ubiquitination of LRIG1 for Met degradation. in Scientific reports 2014
LRIG1 expression may represent a barrier to EMT (show ITK Antibodies)
LRIG1 role in the atrophic epidermis
Downregulation of LRIG1 expression in oral verrucous carcinoma tissue is reported.
LRIG1, as a negative mediated gene of tumor, can inhibit biological function of PAs (show PASK Antibodies) via inhibiting PI3K (show PIK3CA Antibodies)/AKT (show AKT1 Antibodies) and Ras/Raf (show RAF1 Antibodies)/ERK (show EPHB2 Antibodies) pathways, and it might be a new target for gene therapy ofPituitary adenomas
LRIG1 and Fascin-1 (show FSCN1 Antibodies) were differently expressed in cancer and normal lung tissue in patients with NSCLC, which could be a biomarker for mediastinal lymph node metastasis in NSCLC patients.
Results suggest that the LRIG1could negatively control MRP-1 (show MDM4 Antibodies) and the apoptosis to improve the sensitivity of VP16-related chemotherapy.
ERa-dependent expression of LRIG1 dampens ErbB3 (show ERBB3 Antibodies) signaling in luminal breast cancer cells, and by blocking ERa activity with fulvestrant, LRIG1 is decreased thus permitting ErbB3 (show ERBB3 Antibodies) accumulation, enhanced ErbB3 (show ERBB3 Antibodies) signaling to cell survival pathways
These findings demonstrate that LRIG1 is an independent prognostic factor in patients with non-small cell lung cancer
LRIG1 expression was associated with pathological type, differentiation status, and stage of Non-small Cell Lung Cancer. The result showed that LRIG1 was an independent prognostic factor for OS of NSCLC patients.
The inhibitory effects of LRIG1 are most likely mediated by suppression of the EGFR (show EGFR Antibodies)/PI3K (show PIK3CA Antibodies)/AKT (show AKT1 Antibodies) pathway and epithelial-mesenchymal transition (EMT (show ITK Antibodies)) process.
LRIG1+ cells were found to re-populate the neo-epidermis on day 14, suggesting an important homeostatic role of LRIG1 in skin
a subset of human duodenal tumors exhibited features of LRIG1(-/-) adenomas, including loss of LRIG1, gastric metaplasia (MUCIN5AC and MUCIN6), and increased amphiregulin (show AREG Antibodies) and Egfr (show EGFR Antibodies) activity.
LRIG1 regulates the postnatal development of ICC-DMP and ICC-SMP from smooth muscle progenitors in mice.
Loss of one Apc (show APC Antibodies) allele in Lrig1(+) cells results in inducible stem cell-driven model that recapitulates features of familial adenomatous polyposis.
At later stages, Lrig1 expression is sustained in non-sensory tissues, whereas Lrig2 levels are enhanced in neurons and sensory epithelia.
LRIG1 orchestrates corneal-tissue transparency and cell fate during repair via STAT3 (show STAT3 Antibodies).
A review summarizes the data that LRIG1 is a ERBB (show EGFR Antibodies) negative regulator and tumour suppressor.
LRIG1 Loss of heterozygosity (LOH) is frequent across cancers and its loss is an early event in the development of human squamous carcinomas.
The Lrig1, a negative-feedback regulator of the ErbB (show EGFR Antibodies) receptor family, is highly expressed by intestinal stem cells and controls the size of the intestinal stem-cell niche by regulating the amplitude of growth-factor signalling.
Act as a feedback negative regulator of signaling by receptor tyrosine kinases, through a mechanism that involves enhancement of receptor ubiquitination and accelerated intracellular degradation (By similarity).
leucine-rich repeat protein LRIG1
, leucine-rich repeats and immunoglobulin-like domains protein 1
, ortholog of mouse integral membrane glycoprotein LIG-1
, integral membrane glycoprotein